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Oral cancer screening based on methylation frequency
detection in hTERT gene using electrochemical
hybridization assay via a multi–electrode chip coupled with
ferrocenylnaphthalene diimide
Kazuya Haraguchi,[a] Shinobu Sato,[b] Manabu Habu,[a] Naomi Yada,[c] Mana Hayakawa,[a]
Osamu Takahashi,[a] Izumi Yoshioka,[d] Kou Matsuo,[c] Kazuhiro Tominaga,[a] and Shigeori Takenaka*[b]
Abstract: Ferrocenylnaphthalene diimide-based electro-
chemical hybridization assay via a multi-electrode chip
was applied to detect the methylation frequency in the
promoter region of human telomerase reverse transcriptase
(hTERT) gene for clinical samples from tissues, local
exfoliated oral cells from a lesion, or from entire oral
cavity after their methylation specific PCRs. These
methylation frequencies were increased with cancer
progress as the following order: healthy volunteers, oral
leukoplakia as precancerous lesion, and oral squamous
cell carcinoma (OSCC). Operating characteristic analysis
of the obtained current data doesn’t only give excellent
discrimination ability of OSCC, but also of oral leukopla-
kia from healthy volunteers for all samples. Sensitivity
and specificity was 95% and 90%, respectively, which is a
comparable with methods in practical use.
Keywords: Human telomerase reverse transcriptase (hTERT) gene · aberrant methylation · oral cancer screening
1. Introduction
Oral cancer diagnosis under early stage is not only very
important from standpoint of maintenance of normal oral
function, but also extending health span. Until now,
cytological diagnosis, where cells are collected by the
scraping by interdental brush, sponge brush, or swab and
evaluate the presence of atypical cells, is carried out and
subsequently confirmed diagnosis was achieved with
histopathological manifestation from microscopic appear-
ance of incisional biopsy after Hematoxylin-Eosin staining
when precancerous lesion or malignant tumor is sus-
pected.
On the other hand, telomerase is the specialized
ribonucleoprotein complex that caps chromosomal ends
and stabilizes telomeres by adding “TTAGGG” repeats to
the end of chromosomes. Since telomerase activity express
in most human cancers but usually not in normal somatic
cells [1], telomerase has been focused as diagnostic
marker for the purpose of the early detection of human
cancers [2]. We have been developing an electrochemical
telomerase assay as an indicator of telomerase activity to
diagnose oral cancer under early stage [3, 4]. Human
telomerase reverse transcriptase (hTERT) is a major
component of telomerase and it is known that hTERT
expression has been detected in about 85-95% of human
malignant tissues [6], and epigenetic hypermethylation in
the CpG-rich sequences in the increases during human
carcinogenesis [5]. hTERT Promoter regions of hTERT
gene plays an important role in the regulation of hTERT
expression [7]. Our search of the literature revealed no
reports which analyze the methylation status in the
promoter region in hTERT gene using exfoliated oral cells
sample. On the other hand, hyper methylation of CpG
sites in promoter region of hTERT gene, which is corded
gene of active site of telomerase, observed in stomach or
bowel cancer and is expected as cancer marker [8].
Several methods for the analysis of methylation status
have been reported; methylation-specific PCR (MSP),
bisulfite genomic sequencing, real time MSP, MethyLight,
combined bisulfate restriction analysis (COBRA) and
pyrosequencing [9]. These methods have some disadvan-
tages such as complicated operations and high-cost
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running. To overcome such disadvantage, we reported
methylated DNA detection method using the ferrocenyl-
naphthalene diimide (FND)-based electrochemical hy-
bridization assay (EHA) as shown in Figure 1 A. This
simple technique is based on fact that FND (Figure 1B) is
concentrated double-stranded DNA specifically by
threading intercalation [10]. We applied the electrochem-
ical hybridization assay for PCR products from synthetic
oligonucleotide, genome DNA from one oral squamous
cell carcinoma (OSCC) patient, and one healthy volunteer
as template using multi-electrode chip to detect methyl-
ation frequency of CpG sites of hTERT promoter regions
[11]. The obtained results showed that methylation
frequency of sample DNAs was realized by the electro-
chemical hybridization assay with DNA probes carrying
different amounts of methylation on the chip and also
showed the good correlation between cancer development
and methylation frequency [11]. This shows the usefulness
of this method as an oral cancer diagnosis.
Here, methylation frequency of the promoter region in
hTERT gene was searched using for 35 patients of oral
squamous cell carcinoma (OSCC) in addition to 25 oral
leukoplakia patients, or 34 healthy volunteers, and stat-
istical analysis was performed from these results. Oral
leukoplakia is one of precancerous lesion and its diagnosis
is necessary because of its malignant transformation rate
of 4–20% [12]. Furthermore, the results from the electro-
chemical DNA chip was immunohistochemical compared
with the expression level of hTERT protein. Especially,
samples used in this work were collected by the scraping
by sponge brush assuming (EOC-E) as a self-diagnosis
system by the patient’s own or by the scraping by
interdental brush assuming (EOC-L) as diagnostic system
by dentists in general dental hospital.
2. Experimental
2.1 Materials
FND was synthesized by the procedure previously
reported [12]. Oligonucleotides were custom synthesized
by Genenet (Fukuoka, Japan). The sequences of probe
DNAwhich are disulfide derivatives are shown in Table 1.
PCR primers were as follows: MF primer; 5’-GAG GTA
TTT CGG GAG GTT TCG C-3’, MR primer; 5’-ACT
CCG AAC ACC ACG AAT ACC G-3’. RNase-free
water, Formamide (Deionized), 20 3 SSC (0.30 M Sodium
citrate, 3.0 M NaCl, pH 7.0), 2.0 M potassium acetate
(AcOH-AcOK, pH 5.5), 3.0 M KCl and 5.0 M NaCl were
purchased from Life technologies (Carlsbad, CA, USA).
L(+)-Ascorbic acid was purchased from Wako Pure
Chemical Industries, Ltd (Osaka, Japan). DNeasy Blood
and Tissue Kit, BisulFlash DNA Modification Kit and
ZymoTaq Premix were purchased from Qiagen GmbH
(Hilden, Germany), EpiGentek (Farmingdale NY, USA),
and Zymo Research (Orange, CA, USA).
2.2 Clinical Samples
This research was approved by the ethics committee of
Kyushu Dental University, Kitakyushu, Japan (Approval
Number 14-45). Clinical samples (Table 2) were collected
from OSCC, oral leukoplakia, and healthy volunteers
after obtaining informed consent. Procedure of sample
treatment was detailed in supporting materials. Clinical
specimens were tissue, local exfoliated oral cells (EOC-E)
and exfoliated oral cells from entire oral cavity (EOC-L).
Methylation specific PCR (MSP) products from clinical
samples were treated by using DNeasy Blood and Tissue
Kit, BisulFlash DNA Modification Kit and PCR with
ZymoTaq Premix according to a procedure described
previously [11].
Fig. 1. (A) Strategy of electrochemical hybridization assay (EHA), (B) structure of FND, (C) map of hTERT promoter region showing
probe region and primers used for MSP (MF primer and MR primer).
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2.3 Electrochemical Hybridization Assay (EHA)
Custom-made multi-electrode chip (Tanaka Kikinzoku
Kogyo K. K., Tokyo, Japan), carrying 10 working electro-
des, one counter electrode, and one reference electrode,
was used as a sensor chip (Figure S1).
Probe DNAs (Table 1) were immobilized to a multi-
electrode chip according to the pattern of probe DNA by
the previously reported method [11]. Reaction mixture,
0.25 ng/mL MSP products, 53SSC and 50% Formamide
(Deionized)) was incubated for 15 minutes at 958C, after
that, it was stored at 4 8C until use. Hybridization with the
reaction mixture was carried out by soaking a probe
DNA-immobilized electrode in 4.0 mL of reaction mixture
for 2 h at 20 8C. Differential Pulse Voltammetry (DPV)
was measured in 0.20 M AcOK-AcOH, 0.20 M KCl, 5.0
mM FND and 10 mM L(+)-ascorbic acid solution by using
IM-AN100 before and after hybridization (Figure 1). The
following parameters for DPV measurement were em-
ployed“; Initial Voltage=-0.1 V; final Voltage=0.3 V;
Increasing Voltage=10 mV; amplitude=0.05 V; pulse
width=0.025 s; sample width=0.005 s; pulse period=
0.01 s; quiet time=2 s; and resistance=510 kW. All
measurement data were standardized using Di values,
which are defined as (i/i0-1) 3 100 %, where i0 and i refer
to the current value of DPV before and after hybrid-
ization, respectively.
2.4 Statistical Analysis
The results of EHA analyzed using by the Student t test.
All analyses were performed using Microsoft Excel 2010
(Microsoft Corporation, Redmond, WA, USA). Differ-
ences with p values of less than 0.05 were considered
significant.
3. Results and Discussion
3.1 Electrochemical Hybridization Assay
PCR primer containing 24-mer sequence carrying five
CpG sites in 121-mer region of hTERT promoter (Fig-
ure 1C) was selected to be around 58oC of Tm values of its
duplex after bisulfate treatment using CpGWare software
(http://apps.serologicals.com/CPGWARE/dna_
form2.html). DNA probe sequences (M0, M1, M1’, M2,
M2’, M3, M3’, M4, M4’, and M5) were prepared with ten
different methylation frequency containing from one to
five methylated sites [10] as shown in Table 1. Clinical
samples were amplified with PCR using methylation
specific primer and the obtained PCR products were
treated with the electrochemical DNA chip. Typical DPV
data for OSCC samples were included in Figure S2 as ESI
as follows. Figure 2 shows current shift, current shifts in
M4, M4’, and M5 for higher methylated probes were
higher than other probes in the case of OSCC (Fig-
ure 2 A). Current shifts for healthy peoples were totally
Table 1. Probe DNA sequences immobilized on the electrodes.
Probe
DNA
Sequence
M5(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TCG CGT TTA
CGC GTT TTC GTT-3’
M4(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TCG CGT TTA
CGC GTT TTT GTT-3’
M4’(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TTG CGT TTA
CGC GTT TTC GTT-3’
M3(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TCG CGT TTA
CGT GTT TTT GTT-3’
M3’(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TTG TGT TTACGC
GTT TTC GTT-3’
M2(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TCG CGT TTATGT
GTT TTT GTT-3’
M2’(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TTG TGT TTATGC
GTT TTC GTT-3’
M1(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TCG TGT TTATGT
GTT TTT GTT-3’
M1’(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TTG TGT TTATGT
GTT TTC GTT-3’
M0(+) 5’-HO-(CH2)6-S-S-(CH2)6-TAG TTG TGT TTATGT
GTT TTT GTT-3’
Table 2. Number of clinical samples
n
Tissue EOC-L EOC-E
OSCC 35 22 21
oral leukoplakia 25 24 20
healthy volunteers 34 23 29
Fig. 2. Current increasing rate of the multi-electrode chip after
hybridization with the genomic DNAs from the tissue (A),
EOCL (B) and EOCE sample (C) from OSCC (Black bar),
oral leukoplakia (Gray bar) and healthy volunteers (White bar)
treated with bisulfite modification and MSP.
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lower values, which are in agreement with data reported
previously. In the case of oral leukoplakia as a precancer-
ous lesion, relative larger values shows in the case for 1–3
methylated probes of M1, M1’, M2, M2’, M3, and M3’.
Previous paper [11] reported by us showed the current
shifts of 80%, 60%, and 40% for fully matched, single
mismatched, and two mismatched hybrids, respectively
and current shift increased with increase of target DNA.
We applied the electrochemical hybridization assay for
PCR products from synthetic oligonucleotide, genome
DNA from one oral squamous cell carcinoma (OSCC)
patient, and one healthy volunteer as template using
multi-electrode chip to detect methylation frequency of
CpG sites of hTERT promoter regions [11]. In the case of
our previously paper [11], synthetic oligonucleotide was
used as template of PCR, which contained single
sequence. On the other hand, DNA from clinical samples
were mixture containing different methylation pattern,
which is confirmed by the sequencing of MSP product
from genomic sample [10]. This result leads to slightly
discrepancy of the current shift between the data in this
experiment and in previously paper [11].
According to these behaviours, samples of oral
leukoplakia were expected to form mainly two mis-
matched hybrids with 1–3 methylated probes. When
current shifts for M4 and M5 gave moderate ones, it is
expected these mismatched hybrids carrying different
methylated sites without increasing methylation frequency
because of low current shift for M4 and M5. For example,
when methylated (M) and unmethylated (U) sites were
noted, M3 sequence became to show as 5’-MMMUU-3’
and two mismatched is expected to carry same methyl-
ation number such as 5’-MUMMU-3’, not increased
methylation number such as 5’-MMMMM-3’ and thus
methylation frequency of these samples were expected to
be 1/5 – 3/5, or 20–60%. M3’ probe also showed same
situation with M3. Analysis for oral leukoplakia has been
carried out for p16 [14] or TSPYL5 gene [15] using MSP
and showed the amplification for unmethylated primer
and 30% of amplification for methylated one. However,
this report didn’t know that amplified DNA by methy-
lated primer doesn’t tell 100% methylation or not.
Comparing with these results, EHA analysis using 10-
different DNA probes after MSP gives methylation
frequency of an internal sequence, where we can show
methylation frequency as example of patients of oral
leukoplakia. Similar behaviour was obtained in EOCL
(Figure 2B) or EOCE (Figure 2C).
Under OSCC, M4, M4’, and M5 as DNA probes
carrying higher methylation frequency showed higher
current shift than for other DNA probes, however, under
healthy volunteers, M0, M1, M1’, M2, and M2’ as DNA
probes carrying lower methylation frequency showed
higher current shift than other DNA probes. These results
suggested that misannealing is unfavourable for tissue
sample because of less contamination of normal cell and
that misannealing is favourable for EOCE because of
many contamination of normal cells resulting in the
misannealing amplification of unmethylated DNA and
subsequently higher current shift for M0, M1, M1’, M2,
and M2’.
Relative higher current shifts shows for M1, M1’, M2,
M2’, M3, and M3’ as DNA probe carrying 1–3 methylated
sites for EOCL (Figure 2B) or EOCE (Figure 2C) in
oral leukoplakia like as tissue sample.
3.2 Establishment of Cancer Diagnosis
Figure 3 shows the Box plots using current shift for M5
probe for the highest methylation frequency. Current shift
for oral leukoplakia located middle value between OSCC
and healthy volunteers. Statistics analysis using student-t
test of these data gave a significant deference with p<
0.05. OSCC and healthy volunteers were discriminated
whereas oral leukoplakia couldn’t discriminate from
OSCC, where response of tissue, EOCL, and EOCE
was overlapped with that of OSCC in this order. Figure 2
shows that current shift of M4 and M4’ is larger than that
of M5 for OSCC. Since methylation frequency was 80–
100% for cancer state, evaluation only using M5 loses
signal from data without 100% methylation frequency
resulting in scattered data for OSCC. As shown in Table 3,
80% methylated samples shows double or single mis-
matched, or fully matched DNA duplex with M5, M4, and
M4’ probe and thus high methylation samples were
evaluated using the sum of the current shift from M5, M4,
and M4’ probe (DiM4+M4’+M5).
Thus Box plots using the DiM4+M4’+M5 as shown in
Figure 4. Overlap is rarely met between OSCC, oral
leukoplakia, and healthy volunteers. In this evaluation,
response from OSCC and oral leukoplakia didn’t overlap
in all samples from tissue, EOCL, and EOCE. Discrim-
ination accuracy is improved by this synthetic judgment.
ROC analysis was carried out using DiM4+M4’+M5 value.
ROC analysis was carried out in the case of the
detection of OSCC from all samples (Table 4) and of the
detection of OSCC and oral leukoplakia from all samples
Fig. 3. Box plots of DiM5/% of EHA in Tissue (A), EOC-L (B)
and EOC-E samples (C). *: p<0.01.
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(Table 5). Table 4 shows 0.927–0.970 of the area under the
curve (AUC) under detection of OSCC resulting in high
reliability in this evaluation. Positive diagnosis rates were
86, 90, and 91% for tissue, EOCL, and EOCE,
respectively, using the threshold values (Tissue 96.0%,
EOCL 134%, and EOCE 96.6%). Positive diagnosis
rates were 84, 90, and 88% for tissue, EOCL, and
EOCE, respectively, under the detection of cancer and
precancerous lesion as shown in Table 5, which is similar
performance in the cancer detection. This result doesn’t
only show the usefulness of detection of cancer, but also
of precancerous lesion in this system coupled with the
selection of the threshold of DiM4+M4’+M5.
4. Conclusions
Methylation frequency in the promoter region of hTERT
gene was increased with cancer progress as the following
order: healthy volunteers, oral leukoplakia, and OSCC.
Sensitivity and specificity was 95% and 90%, respectively,
in this method which is a comparable with methods in
practical use (Table 6). When comparing with the specific-
ity, this method is higher than the method using telomer-
ase activity, which is reported previously [3,4]. However,
this method takes 2 h, whereas the method using telomer-
ase activity was finished around 30 min.
This result shows that methylation frequency in
promoter region of hTERT gene increases with cancer
Table 3. Combination between probe DNA (M5, M4, M4) and Target DNA
Probe DNA
M5
3-MMMMM
M4
3-UMMMM
M4
3-MMMMU
Target DNA 5-MMMMM FM 1MM 1MM
5-UMMMM 1MM FM 2MM
5-MUMMM 1MM 2MM 2MM
5-MMUMM 1MM 2MM 2MM
5-MMMUM 1MM 2MM 2MM
5-MMMMU 1MM 2MM FM
Fig. 4. Box plots of DiM4+M4+M5/% of EHA in Tissue (A), EOC-L
(B) and EOC-E samples (C). *: p<0.01.
Table 4. ROC analysis in the case of the detection of OSCC from
all samples.
M5+M4+M4’/ OSCC
OSCC oral leuko-
plakia
healthy volun-
teers
accuracy
rate
AUC
Tissue 30/35 7/25 1/34 86%
(81/94)
0.927
EOC-
L
19/22 4/24 0/23 90%
(62/69)
0.936
EOC-
E
20/21 5/19 0/29 91%
(63/69)
0.970
AUC: area under the curve, Threshold: Tissue 96.0%, EOCL
134%, EOCE 96.6%
Table 5. ROC analysis in the case of the detection of OSCC and
leukoplakia from all samples.
M5+M4+M4’/ OSCC+OL
OSCC oral leuko-
plakia
healthy volun-
teers
accuracy
rate
AUC
Tissue 33/35 16/25 4/34 84%
(79/94)
0.906
EOC-
L
22/22 18/24 1/23 90%
(62/69)
0.919
EOC-
E
21/21 14/19 3/29 88%
(61/69)
0.904
AUC: area under the curve, Threshold: Tissue 74.6%, EOCL
71.4%, EOCE 63.2%
Table 6. Sensitivity and specificity of cancer diagnosis methods
Method Sensitivity/
%
Specificity/
%
Ref.
Colon CEA (carcinoembryonic
antigen)
36 87 16
Colon PAI-1 (plasminogen activa-
tor inhibitor1)
94 84 16
Lung PET (positron emission to-
mogram)
70 84 17
Breast Mammography 84 91 18
Oral TRAP assay 14 59 3
Oral Electrochemical Telomer-
ase assay
93 86 3
Oral EHA (This paper) 95 90
Full Paper
www.electroanalysis.wiley-vch.de  2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Electroanalysis 2017, 29, 1–7 5
These are not the final page numbers! 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
development as obtained the good marker of oral cancer
diagnosis under early stage. Furthermore, this method
should open diagnosis system by the patient’s own or by
dentist in general dental hospital.
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